| Bioactivity | Antitumor agent-86 (compound 5a) inhibits MCF-7 breast cancer cells with an IC50 value of 2.62 µM. Antitumor agent-86 induces cell apoptosis and cell cycle arrest, and shows antineoplastic activity by targeting RAS/PI3K/Akt/JNK signaling cascades[1]. |
| Invitro | Antitumor agent-86 (0-200 μM；48 h) 剂量依赖性地抑制 MCF-7，MDA-MB-231，Caco-2 和 PANC-1 癌细胞的增殖，IC50 值分别为 2.617、6.778、14.8 和 23.58 μM[1]。Antitumor agent-86 (2.62 μM；48 h) 诱导细胞凋亡、细胞周期阻滞，降低 MCF-7 细胞的 p-RAS 蛋白水平、PI3K 和 Akt 的 mRNA 转录水平和 p-JNK 蛋白的表达[1]。Antitumor agent-86 (2.62 μM；48 h) 上调 p21 基因的表达水平[1]。 Cell Proliferation Assay[1] Cell Line: |
| Name | Antitumor agent-86 |
| Formula | C29H31N5O2S |
| Molar Mass | 513.65 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Salem MM, et al. Synthesis, molecular docking, and in-vitro studies of pyrimidine-2-thione derivatives as antineoplastic agents via potential RAS/PI3K/Akt/JNK inhibition in breast carcinoma cells. Sci Rep. 2022 Dec 22;12(1):22146. |